MPR Weekly Dose 117 — Guidance on Paxlovid Tx; Dupixent Approval; Plaque Psoriasis Cream Approved; COVID-19 Vaccine Response in Under 5s; CDC Monkeypox Alert

The latest guidance for Paxlovid treatment following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; Update on the efficacy of a COVID-19 vaccine in those aged under 5; And the latest on Monkeypox.

Episode metadata supplied by the publisher feed · Published May 27, 2022

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose 117 — Guidance on Paxlovid Tx; Dupixent Approval; Plaque Psoriasis Cream Approved; COVID-19 Vaccine Response in Under 5s; CDC Monkeypox Alert

0:00 12:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 12 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on May 27, 2022.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!